Ian E. Templeton

644 total citations
18 papers, 421 citations indexed

About

Ian E. Templeton is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, Ian E. Templeton has authored 18 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 11 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Ian E. Templeton's work include Pharmacogenetics and Drug Metabolism (12 papers), Drug Transport and Resistance Mechanisms (9 papers) and Melanoma and MAPK Pathways (2 papers). Ian E. Templeton is often cited by papers focused on Pharmacogenetics and Drug Metabolism (12 papers), Drug Transport and Resistance Mechanisms (9 papers) and Melanoma and MAPK Pathways (2 papers). Ian E. Templeton collaborates with scholars based in United States, United Kingdom and South Korea. Ian E. Templeton's co-authors include Kent L. Kunze, Nina Isoherranen, Kenneth E. Thummel, Luna Musib, C. Davis, Nicholas S. Jones, Christine Hoffer, E D Kharasch, Wendel L. Nelson and Eric D. Kantor and has published in prestigious journals such as Blood, Clinical Pharmacology & Therapeutics and Drug Metabolism and Disposition.

In The Last Decade

Ian E. Templeton

18 papers receiving 402 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ian E. Templeton United States 9 212 118 102 80 53 18 421
Kiran C. Patki United States 7 245 1.2× 137 1.2× 58 0.6× 62 0.8× 50 0.9× 13 435
I. Gardner United Kingdom 10 195 0.9× 103 0.9× 133 1.3× 60 0.8× 43 0.8× 17 510
Cornelia M. Smith United States 6 258 1.2× 126 1.1× 110 1.1× 61 0.8× 70 1.3× 7 574
Faraz Kazmi United States 10 246 1.2× 156 1.3× 194 1.9× 56 0.7× 55 1.0× 17 591
Lilly Xu United States 7 236 1.1× 148 1.3× 87 0.9× 40 0.5× 38 0.7× 8 425
Otito F. Iwuchukwu United States 11 218 1.0× 93 0.8× 132 1.3× 91 1.1× 41 0.8× 31 566
Anthony Harrison United Kingdom 10 259 1.2× 220 1.9× 101 1.0× 95 1.2× 62 1.2× 15 536
R Temple United States 4 261 1.2× 192 1.6× 113 1.1× 114 1.4× 70 1.3× 5 554
Yasushi Yoshigae Japan 14 165 0.8× 164 1.4× 144 1.4× 81 1.0× 39 0.7× 27 568

Countries citing papers authored by Ian E. Templeton

Since Specialization
Citations

This map shows the geographic impact of Ian E. Templeton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian E. Templeton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian E. Templeton more than expected).

Fields of papers citing papers by Ian E. Templeton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian E. Templeton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian E. Templeton. The network helps show where Ian E. Templeton may publish in the future.

Co-authorship network of co-authors of Ian E. Templeton

This figure shows the co-authorship network connecting the top 25 collaborators of Ian E. Templeton. A scholar is included among the top collaborators of Ian E. Templeton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian E. Templeton. Ian E. Templeton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Ballard, T. Eric, Liming Zhang, Lawrence H. Cohen, et al.. (2025). Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition. Clinical Pharmacology in Drug Development. 14(5). 368–381. 1 indexed citations
2.
Jaiswal, Swati, et al.. (2023). Real-world application of physiologically based pharmacokinetic models in drug discovery. Drug Metabolism and Disposition. 53(1). 100015–100015. 8 indexed citations
3.
Templeton, Ian E., Karen Rowland Yeo, Hannah M. Jones, et al.. (2023). Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for Tucatinib. Clinical Pharmacology & Therapeutics. 115(2). 299–308. 3 indexed citations
4.
5.
Amore, Benny, Nikunjkumar Patel, Priya Batheja, et al.. (2023). Physiologically Based Pharmacokinetic Model Development and Verification for Bioequivalence Testing of Bempedoic Acid Oral Suspension and Reference Tablet Formulation. Pharmaceutics. 15(5). 1476–1476. 3 indexed citations
6.
7.
Templeton, Ian E., Terry Podoll, Cecile M. Krejsa, & J. Greg Slatter. (2020). A Mechanistic Physiologically Based Pharmacokinetic (PBPK) Drug Interaction Model for the Mouse Double Minute 2 (MDM2) Inhibitor KRT-232. Blood. 136(Supplement 1). 9–10. 2 indexed citations
8.
Cheeti, Sravanthi, Yuzhong Deng, Ilsung Chang, et al.. (2020). Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics. Clinical Pharmacology in Drug Development. 10(2). 144–152. 6 indexed citations
9.
Templeton, Ian E., Nicholas S. Jones, & Luna Musib. (2018). Pediatric Dose Selection and Utility of PBPK in Determining Dose. The AAPS Journal. 20(2). 31–31. 58 indexed citations
10.
Templeton, Ian E., Paulien Ravenstijn, Carlo Sensenhauser, & Jan Snoeys. (2015). A physiologically based pharmacokinetic modeling approach to predict drug–drug interactions between domperidone and inhibitors of CYP3A4. Biopharmaceutics & Drug Disposition. 37(1). 15–27. 11 indexed citations
11.
Templeton, Ian E. & Luna Musib. (2015). MEK inhibitors beyond monotherapy: current and future development. Current Opinion in Pharmacology. 23. 61–67. 17 indexed citations
12.
Templeton, Ian E., Gary Eichenbaum, Rucha Sane, & Jin Zhou. (2014). Case Study 5. Deconvoluting Hyperbilirubinemia: Differentiating Between Hepatotoxicity and Reversible Inhibition of UGT1A1, MRP2, or OATP1B1 in Drug Development. Methods in molecular biology. 1113. 471–483. 8 indexed citations
13.
Templeton, Ian E., J. Brian Houston, & Aleksandra Galetin. (2011). Predictive Utility of In Vitro Rifampin Induction Data Generated in Fresh and Cryopreserved Human Hepatocytes, Fa2N-4, and HepaRG Cells. Drug Metabolism and Disposition. 39(10). 1921–1929. 17 indexed citations
14.
Templeton, Ian E., et al.. (2011). Evaluation of 6β-Hydroxycortisol, 6β-Hydroxycortisone, and a Combination of the Two as Endogenous Probes for Inhibition of CYP3A4 In Vivo. Clinical Pharmacology & Therapeutics. 89(6). 888–895. 63 indexed citations
15.
Templeton, Ian E., et al.. (2010). Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by Itraconazole and Its Metabolites From In Vitro Inhibition Data. Clinical Pharmacology & Therapeutics. 88(4). 499–505. 54 indexed citations
16.
Templeton, Ian E., Kenneth E. Thummel, E D Kharasch, et al.. (2007). Contribution of Itraconazole Metabolites to Inhibition of CYP3A4 In Vivo. Clinical Pharmacology & Therapeutics. 83(1). 77–85. 103 indexed citations
17.
Slatter, J. Greg, Ian E. Templeton, John C. Castle, et al.. (2006). Compendium of gene expression profiles comprising a baseline model of the human liver drug metabolism transcriptome. Xenobiotica. 36(10-11). 938–962. 26 indexed citations
18.
Anderson, Gail D., Gary W. Elmer, Eric D. Kantor, Ian E. Templeton, & Michael V. Vitiello. (2005). Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects. Phytotherapy Research. 19(9). 801–803. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kiran C. Patki Breakdown of academic impact, for papers by I. Gardner Breakdown of academic impact, for papers by Cornelia M. Smith Breakdown of academic impact, for papers by Faraz Kazmi Breakdown of academic impact, for papers by Lilly Xu Breakdown of academic impact, for papers by Otito F. Iwuchukwu Breakdown of academic impact, for papers by Anthony Harrison Breakdown of academic impact, for papers by R Temple Breakdown of academic impact, for papers by Yasushi Yoshigae
Rankless by CCL
2026